In weight loss battle, Novo and Lilly face growing offensive from licensed copies
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...
This Is Huge News for Eli Lilly Investors
Eli Lilly just gave investors several reasons to cheer.
Ozempic MDL Expands to Include New Drugs, but Not New Injuries
"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...
Ozempic lures people to the doctor, Nestle's GLP-1 'shot,' an FDA Zepbound ruling: Pharma news roundup
Nestle just rolled out a new protein shot drink that it says will help people looking to lose weight manage their hunger and ...
MIT Technology Review1d
Drugs like Ozempic now make up 5% of prescriptions in the US
“Among adults, 5.4% of all prescriptions in September 2024 were for GLP-1s,” Rodriguez says. That is up from 3.5% a year ...
FiercePharma2d
FDA reaffirms decision to erase Eli Lilly's tirzepatide from shortage list, halting future flow of knockoffs
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
RFK Jr. on Ozempic, Eli Lilly's next test, and Elon Musk gets on the bandwagon: Pharma news roundup
Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...
NJBIZ2d
EU reportedly reviewing link between Ozempic, rare eye disease
With U.S. headquarters in Plainsboro, Novo Nordisk told NJBIZ, "NAION is a very rare eye disease, and it is not an adverse ...
CNN on MSN1d
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli ...